Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post‐hoc analysis of a double‐blinded, randomised, crossover trial
Open Access
- 27 October 2025
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (1) , 427-433
Abstract
Background: There is little data on how semaglutide affects basal versus bolus insulin and dosing parameters in adults with type 1 diabetes on insulin pump therapy. Methods: This is a post‐hoc analysis of a double‐blinded, randomised, crossover trial assessing semaglutide (up to 1 mg) versus placebo during automated insulin delivery (AID). This analysis focuses on the first 11 of 15 weeks where participants used their routine pump therapy with continuous glucose monitoring (CGM), where remote follow‐ups were performed on days 7, 21, 32, 56, 63, and 77 (± 4 days). Changes in insulin requirements, carbohydrate input, and pump parameters over time compared to baseline were assessed, as well as the frequency of parameter adjustments. Results: Twenty‐six participants were included; 100% were using CGM and 81% using AID at baseline. Daily total and bolus insulin, along with carbohydrate input, were significantly reduced by day 7 and remained so, while basal was significantly reduced by day 32. By day 77, there was a median increase in carbohydrate ratios by 4.1% [−1.8, 7.7] and in correction factors by 11.2% [0.0, 20.8], and a reduction in pre‐programmed basal rates by 7.9% [−12.7, −4.2]. The median time spent in hypoglycemia was rarely >4% during these follow‐ups. Conclusions: Insulin needs decrease rapidly upon initiation of semaglutide use in type 1 diabetes on pump therapy, predominantly due to bolus changes from less carbohydrate consumption. While diabetes technology helps to reduce hypoglycemia, adjustments to pump dosing are still required.Keywords
Funding Information
- Canada Research Chairs
This publication has 24 references indexed in Scilit:
- Semaglutide in Adults with Type 1 Diabetes and ObesityNEJM Evidence, 2025
- Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trialNature Medicine, 2025
- GLP-1 Receptor Agonist and SGLT2 Inhibitor Prescribing in People With Type 1 DiabetesJAMA, 2024
- Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetesDiabetes, Obesity and Metabolism, 2024
- Effect of low dose Semaglutide in people with Type 1 Diabetes and excess weightDiabetes Research and Clinical Practice, 2024
- Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 DiabetesDiabetes Technology & Therapeutics, 2024
- Longitudinal Trends in Glycemic Outcomes and Technology Use for Over 48,000 People with Type 1 Diabetes (2016–2022) from the T1D Exchange Quality Improvement CollaborativeDiabetes Technology & Therapeutics, 2023
- Glucagon‐like peptide ‐1 receptor agonists as adjunctive treatment for type 1 diabetes: Renewed opportunities through tailored approaches?Diabetes, Obesity and Metabolism, 2022
- Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double‐blinded, placebo‐controlled trialDiabetes, Obesity and Metabolism, 2019
- The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trialDiabetologia, 2012